A double dose of vaccine news have helped to boost US stocks [Video]
|Listen to the latest market mood for the S&P500.
The risk tone has been broadly higher over the last week in the markets as a double dose of vaccine news boosted risk sentiment, and US stocks, higher. The Pfizer/BioNtech vaccine news last week and the Moderna vaccine news yesterday have all helped to boost US stocks.
Although wider questions do remain in the near term about how COVID-19 cases will drag on economies short term, the bigger picture is positive for stocks deep into 2021. On top of this seasonally the S&P500 does very will at the end of November in the run up to early December. In the last 10 years the S&P500 has only lost twice between 22 Nov and 2 December.
Therefore, expect S&P500 buyers on pullbacks.
Trade Risks: The main risk to this trade is if there is a negative change in the risk tone and/or the US has a national lockdown.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.